CCG-100602
- Product Name
- CCG-100602
- CAS No.
- 1207113-88-9
- Chemical Name
- CCG-100602
- Synonyms
- CCG-100602;CCG-100602 >=98% (HPLC);1-[3,5-bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)piperidine-3-carboxamide;3-Piperidinecarboxamide, 1-[3,5-bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)-;CCG 100602,Inhibitor,transcription,inhibit,serum,myocardin,nuclear,SRF,CCG100602,MRTF-A,CCG-100602,Ras,localization
- CBNumber
- CB02590547
- Molecular Formula
- C21H17ClF6N2O2
- Formula Weight
- 478.82
- MOL File
- 1207113-88-9.mol
CCG-100602 Property
- storage temp.
- -20°C
- solubility
- ≤0.2mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide
- form
- powder
- color
- white to beige
N-Bromosuccinimide Price
- Product number
- SML2292
- Product name
- CCG-100602
- Purity
- ≥98% (HPLC)
- Packaging
- 5mg
- Price
- $63.1
- Updated
- 2024/03/01
- Product number
- SML2292
- Product name
- CCG-100602
- Purity
- ≥98% (HPLC)
- Packaging
- 25mg
- Price
- $179
- Updated
- 2024/03/01
- Product number
- 10787
- Product name
- CCG-100602
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $38
- Updated
- 2024/03/01
- Product number
- 10787
- Product name
- CCG-100602
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $71
- Updated
- 2024/03/01
- Product number
- 10787
- Product name
- CCG-100602
- Purity
- ≥98%
- Packaging
- 25mg
- Price
- $166
- Updated
- 2024/03/01
CCG-100602 Chemical Properties,Usage,Production
Uses
The Rho family of small GTPases play an important role in transduction of cell signaling events associated with several human cancers. CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. The site of inhibition in the pathway is not precisely defined but CCG-1423 appears to act on some aspect of the interaction of SRF with its transcriptional cofactor megakaryoblastic leukemia 1 (MKL1) at a point upstream of DNA binding. CCG-100602 is a CCG-1423 analog developed for improved selectivity, potency, and attenuated cytotoxicity relative to its parent compound. CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells with an IC50 value of 9.8 μM. At 100 μM, CCG-100602 demonstrates 72% inhibition of PC-3 cell invasion into a Matrigel model of metastasis, exhibiting an efficacy:toxicity profile superior to that of CCG-1423 at 10 μM.[Cayman Chemical]
Biological Activity
ccg-100602 is a rho pathway inhibitor.rho, a member of the ras superfamily of small gtp-binding proteins, plays a key role in various biological processes including microtubule dynamics, gene transcription, actin cytoskeleton organization, cell cycle progression, oncogenic transformation, as well as epithelial wound repair.
in vitro
ccg-100602 was developed as a ccg-1423 analog for improved selectivity, potency, and attenuated cytotoxicity. it was found that ccg-100602 was able to inhibit rhoa/c-mediated and srf-driven luciferase expression in pc-3 prostate cancer cells. at 100 μm, ccg-100602 showed 72% inhibition of pc-3 cell invasion into a matrigel model of metastasis, having an superior efficacy-toxicity profile to that of ccg-1423 [1].
in vivo
to evaluate whether inhibition of srf could protect podocytes from hyperglycaemia injury, daily ip administration of ccg-1423 was performed in dm rata. results showed that ccg-1423 could ameliorate proteinuria dose-dependently. ccg-1423 at 0.02 mg/kg could significantly reduce the body weight, compared with the vehicle controls. in addition, the inhibition of srf with ccg-1423 also significantly abrogated the reduction of synaptopodin expression and the induction of srf,α-sma, fsp-1 expression in renal cortex tissues [2].
IC 50
9.8 μm for pc-3 prostate cancer cells
References
[1] evelyn, c. r.,bell, j.l.,ryu, j.g., et al. design, synthesis and prostate cancer cell-based studies of analogs of the rho/mkl1 transcriptional pathway inhibitor, ccg-1423. bioorganic & medicinal chemistry letters 20, 665-672 (2010).
[2] zhao l, wang x, sun l, nie h, liu x, chen z, guan g. critical role of serum response factor in podocyte epithelial-mesenchymal transition of diabetic nephropathy. diab vasc dis res. 2016 jan;13(1):81-92.
CCG-100602 Preparation Products And Raw materials
Raw materials
Preparation Products
CCG-100602 Suppliers
- Tel
- 021-52996696，15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4121
- Advantage
- 55
- Tel
- 17754423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 7998
- Advantage
- 62
- Tel
- QQ:65489617 15618227136
- Fax
- 21-5161 9052
- info@SuperLan-chem.com
- Country
- China
- ProdList
- 9445
- Advantage
- 58
- Tel
- +1-781-999-5354 +1-00000000000
- marketing@targetmol.com
- Country
- United States
- ProdList
- 19892
- Advantage
- 58
- Tel
- +1-708-310-1919 +1-13798911105
- Fax
- 708-557-7486
- sales@invivochem.cn
- Country
- United States
- ProdList
- 6393
- Advantage
- 58
- Tel
- 021-58447131 13564518121
- sales@dcchemicals.com
- Country
- China
- ProdList
- 9414
- Advantage
- 58
- Tel
- 18818260767
- Fax
- QQ 3610331285
- sales@chemegen.com
- Country
- China
- ProdList
- 11289
- Advantage
- 58
- Tel
- 021-58432009 400-005-6266
- Fax
- 021-58436166
- marketing1@energy-chemical.com
- Country
- China
- ProdList
- 44894
- Advantage
- 58
- Tel
- 021-69568360 18916172912
- order@med-bio.cn
- Country
- China
- ProdList
- 8141
- Advantage
- 58
- Tel
- 2717893647 14768611851
- 486064515@qq.com
- Country
- China
- ProdList
- 864
- Advantage
- 58